Effects of strong and moderate CYP3A4 inducers on the pharmacokinetics of fedratinib in healthy adult participants
Sign Up to like & getrecommendations! Published in 2021 at "Cancer Chemotherapy and Pharmacology"
DOI: 10.1007/s00280-021-04292-4
Abstract: Fedratinib is an oral and selective Janus kinase 2 inhibitor that is indicated for treatment of adults with intermediate-2 or high-risk primary or secondary myelofibrosis. Fedratinib is metabolized by cytochrome P450s (CYPs), primarily CYP3A4. The… read more here.
Keywords: moderate cyp3a4; healthy adult; strong moderate; rifampin ... See more keywords
Abstract 4341994: Penetrance of Cardiomyopathy-Associated Variants in a Population-Based Cohort Supports ClinGen Gene Validity Classifications
Sign Up to like & getrecommendations! Published in 2025 at "Circulation"
DOI: 10.1161/circ.152.suppl_3.4341994
Abstract: Introduction: Cardiomyopathies, including hypertrophic (HCM) and dilated (DCM), are heterogeneous heart muscle disorders contributing significantly to heart failure, arrhythmias, and sudden cardiac death. While guidelines recommend genetic testing for affected individuals and relatives, uncertainty persists… read more here.
Keywords: clingen; definitive strong; cohort; penetrance ... See more keywords